TheraRadar
Clinical-Stage Companies / Genfit

Genfit

Pre-Approval PRO BETA
22
Total Trials
1
Phase 3
11
Phase 2
1
Recruiting
146
Score

Pipeline by Phase

Phase 3
1
Phase 2
11
Phase 1
11

Therapeutic Focus

Abdominal Obesity Renal Impairment Healthy Pharmacokinetics Cholangiocarcinoma

Clinical Trials (22)

NCT02704403 Phase 3 TERMINATED

Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)

Started: 3/1/2016

NCT05900050 Phase 2 TERMINATED

Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®

Started: 7/2/2023

NCT06987968 Phase 2 TERMINATED

A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy

Started: 8/25/2025

NCT01694849 Phase 2 COMPLETED

Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)

Started: 9/1/2012

NCT03883607 Phase 2 TERMINATED

Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)

Started: 6/25/2019

NCT03953456 Phase 2 TERMINATED

Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)

Started: 8/16/2019

NCT03124108 Phase 2 COMPLETED

Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid

Started: 4/5/2017

NCT01271777 Phase 2 COMPLETED

Pilot Study With GFT505 (80mg) in Patients With Insulin Resistance and Abdominal Obesity

Started: 1/1/2011

NCT01261494 Phase 2 COMPLETED

Study With GFT505 (80mg) Versus Placebo in Patients With Type 2 Diabetes Mellitus

Started: 12/1/2010

NCT01275469 Phase 2 COMPLETED

Pilot Study With GFT505 (80mg) in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity.

Started: 6/1/2009

NCT01271751 Phase 2 COMPLETED

Pilot Study With GFT505 (80mg) in Atherogenic Dyslipidaemic Patients With Abdominal Obesity

Started: 1/1/2009

NCT05874414 Phase 1 RECRUITING

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma

Started: 8/21/2023

NCT07110441 Phase 1 COMPLETED

Pharmacokinetic Study on G1090N (Nitazoxanide) Capsules in Healthy Volunteers

Started: 8/26/2025

NCT05368935 Phase 1 COMPLETED

Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects

Started: 4/25/2022

NCT05116826 Phase 1 COMPLETED

Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients

Started: 11/5/2021

NCT04171752 Phase 1 COMPLETED

Elafibranor Pharmacokinetic Parameters in Elderly Healthy Volunteers

Started: 11/22/2019

NCT03985969 Phase 1 COMPLETED

Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and Indomethacin

Started: 9/23/2019

NCT03844555 Phase 1 COMPLETED

Elafibranor Pharmacokinetic Parameters in Renal Impaired Patients

Started: 2/28/2019

NCT03765671 Phase 1 COMPLETED

Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients

Started: 12/12/2018

NCT02142127 Phase 1 COMPLETED

Mass Balance Study of 14C-labelled GFT505 in Healthy Volunteers

Started: 4/1/2014

NCT02091310 Phase 1 COMPLETED

Phase I Study to Evaluate the Effect of GFT505 on QT/QTc Interval in Healthy Volunteers

Started: 2/1/2014

NCT01474161 Phase 1 COMPLETED

Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505

Started: 11/1/2011

Drug Candidates

GNS561 + Trametinib Single Dose G1090N Multiple dosing of G1090N VS-01 on top of SOC VS-01 on top of SOC (Active Treatment Group) SOC GFT505 80mg GFT505 120mg Placebo Nitazoxanide
Activity Status: Active
Last Trial Started: 8/26/2025
Last Trial Ended: 12/3/2025
Trials (12 months): 2
Completed Trials: 16
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.